Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + pertuzumab
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Trastuzumab + pertuzumab is a fixed-dose combination of two recombinant humanized monoclonal antibodies targeting the human epidermal growth factor receptor 2 (HER2). Both components are produced using Chinese hamster ovary (CHO) cells. Trastuzumab binds to subdomain IV of the HER2 extracellular domain, inhibiting ligand-independent HER2 signaling and inducing antibody-dependent cellular cytotoxicity (ADCC). Pertuzumab binds to subdomain II of HER2, blocking ligand-dependent heterodimerization with other HER family members and further inhibiting downstream signaling. The combination provides complementary mechanisms that result in more comprehensive blockade of the HER2 pathway and enhanced antitumor activity compared to either agent alone. This dual-targeted therapy is primarily indicated for early-stage and metastatic HER2-positive breast cancer in combination with chemotherapy[1][3][6].
- Brand names
- Phesgo赫捷康
- Other names
- Pertuzumab and Trastuzumab Injection帕妥珠曲妥珠单抗注射液曲帕双靶皮下合剂
02
Targets
HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + pertuzumab.